Building an Investable Intellectual Property Portfolio

Innovative life science companies are increasingly looking to create strong Intellectual Property portfolios to attract investors and potential acquirers. This seminar will help highlight the key points for companies to help avoid mistakes when building an IP portfolio and position which will withstand Due Diligence and Freedom To Operate scrutiny.

Our specialist EIP team will guide you through the steps needed in modern (bio)pharma companies to do the right things at the right time to make sure you get good investments and deals.

Inga-Lill Andersson, the head of the EIP Stockholm office and Gareth Probert, the head of the EIP pharma practice, have expertise and experience working for growing (bio)pharma companies as well as performing DD and FTO for investors and big pharma. We know what investors and big pharma companies are looking for in outside companies and can help you get in shape to reach your commercial goals.

Agenda:

• Introduction to the session
• Key elements of IP strategy
• Commercialisation plan
• Teams – employees, CROs and consultants
• Protecting multiple stages of R&D
• Due diligence preparation
• Freedom To Operate
• Q&A

Timings

16:30–18:00 Seminar

18:00–19:00 Networking, food & drinks

Speakers

Inga-Lill Andersson

Gareth Probert